drugset
drugset / Trial / NCT03963362

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

NCT03963362 ↗

Phase 1 Unknown 24 enrolled GL Pharm Tech Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

To evauate pharmacokinetics of GLA5PR tablet according to the renal function

Timeline

Start
2019-09-17
Primary completion
2020-12-31
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GLA5PR Unknown 75 mg —
Subject GLA5PR Unknown 150 mg —

Indications

neuropathy, painful